Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
mAgPLcaAvWS3P3R7